117 related articles for article (PubMed ID: 20961258)
1. Aprepitant for erlotinib-induced pruritus.
Levêque D
N Engl J Med; 2010 Oct; 363(17):1680-1; author reply 1681. PubMed ID: 20961258
[No Abstract] [Full Text] [Related]
2. More on aprepitant for erlotinib-induced pruritus.
Gerber PA; Buhren BA; Homey B
N Engl J Med; 2011 Feb; 364(5):486-7. PubMed ID: 21288112
[No Abstract] [Full Text] [Related]
3. More on aprepitant for erlotinib-induced pruritus.
Mir O; Blanchet B; Goldwasser F
N Engl J Med; 2011 Feb; 364(5):487. PubMed ID: 21288111
[No Abstract] [Full Text] [Related]
4. Aprepitant for erlotinib-induced pruritus.
Vincenzi B; Tonini G; Santini D
N Engl J Med; 2010 Jul; 363(4):397-8. PubMed ID: 20660413
[No Abstract] [Full Text] [Related]
5. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Santini D; Vincenzi B; Guida FM; Imperatori M; Schiavon G; Venditti O; Frezza AM; Berti P; Tonini G
Lancet Oncol; 2012 Oct; 13(10):1020-4. PubMed ID: 22995650
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant for pruritus: drug-drug interactions matter.
Mir O; Coriat R
Lancet Oncol; 2012 Oct; 13(10):964-5. PubMed ID: 22995652
[No Abstract] [Full Text] [Related]
7. Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case report.
Villafranca JJ; Siles MG; Casanova M; Goitia BT; Domínguez AR
J Med Case Rep; 2014 Sep; 8():300. PubMed ID: 25200537
[TBL] [Abstract][Full Text] [Related]
8. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
[TBL] [Abstract][Full Text] [Related]
9. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.
Majumdar AK; McCrea JB; Panebianco DL; Hesney M; Dru J; Constanzer M; Goldberg MR; Murphy G; Gottesdiener KM; Lines CR; Petty KJ; Blum RA
Clin Pharmacol Ther; 2003 Aug; 74(2):150-6. PubMed ID: 12891225
[TBL] [Abstract][Full Text] [Related]
10. The NK1 receptor antagonist aprepitant attenuates NK1 agonist-induced scratching behaviour in the gerbil after intra-dermal, topical or oral administration.
Costantini VJ; Corsi M; Dünstl G; Bettelini L; Zonzini L; Gerrard P
Exp Dermatol; 2015 Apr; 24(4):312-4. PubMed ID: 25650546
[TBL] [Abstract][Full Text] [Related]
11. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
12. Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose.
Muñoz M; Parrilla J; Rosso M; Coveñas R
Acta Derm Venereol; 2019 May; 99(6):620-621. PubMed ID: 30734049
[No Abstract] [Full Text] [Related]
13. Aprepitant for refractory nivolumab-induced pruritus.
Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
[TBL] [Abstract][Full Text] [Related]
14. Aprepitant against pruritus in patients with solid tumours.
Vincenzi B; Fratto ME; Santini D; Tonini G
Support Care Cancer; 2010 Sep; 18(9):1229-30. PubMed ID: 20544226
[No Abstract] [Full Text] [Related]
15. Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.
Jiménez Gallo D; Albarrán Planelles C; Linares Barrios M; Fernández Anguita MJ; Márquez Enríquez J; Rodríguez Mateos ME
Dermatol Ther; 2014; 27(3):178-82. PubMed ID: 24517320
[TBL] [Abstract][Full Text] [Related]
16. EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.
Mak IT; Kramer JH; Chmielinska JJ; Spurney CF; Weglicki WB
J Cardiovasc Pharmacol; 2015 Jan; 65(1):54-61. PubMed ID: 25343568
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.
Marbury TC; Ngo PL; Shadle CR; Jin B; Panebianco D; Caro L; Valentine J; Murphy G
J Clin Pharmacol; 2011 Dec; 51(12):1712-20. PubMed ID: 21209230
[TBL] [Abstract][Full Text] [Related]
18. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
19. Review: hepatotoxicity and EGFR inhibition.
Ramanarayanan J; Krishnan GS
Clin Adv Hematol Oncol; 2008 Mar; 6(3):200-1. PubMed ID: 18391919
[No Abstract] [Full Text] [Related]
20. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
